UNSPSC 51282126: Clometocillin potassium

This classification denotes a penicillin antibiotic C17H17Cl2N2O5S.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7C71K33PDJ, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((2-(3,4-dichlorophenyl)-2-methoxyacetyl)amino)-3,3-dimethyl-7-oxo-, potassium salt (1:1), (2s,5r,6r)-, but more generally known as clometocillin potassium, which bears US NIH Compound Identifier 24892866.

UNSPSC 51282126 Clometocillin potassium is a Commodity code with minimal recent state and local procurement activity directly aligned to its specific pharmaceutical scope. The recent opportunities tagged under this code instead represent a broader pharmaceutical and medical-supply procurement landscape in which state and local governments purchase naloxone systems, generic multi-source pharmaceuticals, over-the-counter products, and emergency medical supplies through competitive bidding and cooperative purchasing vehicles. The issuing bodies span county health departments, state HHS commissions, municipal fire and rescue departments, and multi-state cooperative purchasing alliances. Work solicited includes acquisition of pharmaceutical products (both brand and generic), emergency response supplies, and naloxone distribution systems for community health and first-responder use, typically with compliance requirements around cGMP certification, FDA approval, Drug Supply Chain Security Act (DSCSA) adherence, and expiration-date minimums.

Recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023); the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract amount of $700,000.00 and a sheltered-market set-aside for certified Small Local Business Enterprises (response due March 13, 2026); the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products serving participating state and local facilities across multiple states including Oregon (response due March 26, 2026); and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (response due April 3, 2026). Geographic activity includes Florida, Texas, Minnesota, and Oregon. The code shows activity across municipal, county, state, and multi-state cooperative entities, though the opportunities posted do not match the clometocillin potassium specification closely and appear instead to reflect broader pharmaceutical and emergency-supply procurement.